Seven percent hypertonic saline--0.1% hyaluronic acid in infants with mild-to-moderate bronchiolitis

Area of Science:

• Pediatrics
• Respiratory Medicine
• Pharmacology

Background:

• Bronchiolitis is a common viral respiratory infection in infants, often requiring hospitalization.
• Current treatments for bronchiolitis are primarily supportive, with limited pharmacological interventions.
• Hypertonic saline has shown promise in managing respiratory conditions.

Purpose of the Study:

• To evaluate the efficacy and safety of inhaled 7% hypertonic saline combined with 0.1% hyaluronic acid (7% HS-HA) in infants hospitalized with mild-to-moderate bronchiolitis.
• To compare the clinical severity score, hospitalization duration, and safety of 7% HS-HA versus normal saline (NS).

Main Methods:

• A double-blind, controlled study involving 39 infants under 7 months old hospitalized with bronchiolitis.
• Infants were randomly assigned to receive either nebulized 7% HS-HA or 0.9% NS twice daily for 3 days.
• Clinical severity scores were assessed at admission and throughout hospitalization; hospitalization duration and safety were primary outcomes.

Main Results:

• No significant difference in admission clinical severity scores between the 7% HS-HA and NS groups.
• A trend towards a 14.6% reduction in hospitalization days was observed in the 7% HS-HA group (4.1 days vs. 4.8 days for NS).
• Normal saline (NS) was identified as an independent risk factor for prolonged hospital stay (P=0.04).
• Mild cough was the most common adverse event, occurring in 19% of the 7% HS-HA group and 11% of the NS group.

Conclusions:

• Inhaled 7% HS-HA is a safe and effective therapeutic option for infants hospitalized with mild-to-moderate bronchiolitis.
• The treatment showed a trend towards reducing hospitalization duration.
• Further research may confirm the benefits of 7% HS-HA in bronchiolitis management.